Vedolizumab Maintenance Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial
Brian G. Feagan(Western University), Asit Parikh, Stephen B. Hanauer(Northwestern University), Bruce E. Sands(Icahn School of Medicine at Mount Sinai), William J. Sandborn(University of San Diego), Gert Van Assche(KU Leuven), Silvio Danese(IRCCS Ospedale San Raffaele), Hyo Jong Kim(Soongsil University), Serap Sankoh(Millennium Engineering and Integration (United States)), Jing Xu(Kunming Medical University), Paul Rutgeerts(KU Leuven), Jean–Frédéric Colombel(Icahn School of Medicine at Mount Sinai), Tim Wyant(Curis (United States)), Catherine Milch(Millennium Engineering and Integration (United States)), Jeffrey Axler, Irving H. Fox(Takeda (United States))
Cited by 17
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k